David Green
Abstract
Most patients with severe aplastic anemia (SAA) are treated with horse antithymocyte globulin (ATG) and cyclosporine, a regimen that achieves a
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Most patients with severe aplastic anemia (SAA) are treated with horse antithymocyte globulin (ATG) and cyclosporine, a regimen that achieves a
Key concepts: Medicine, Alemtuzumab, Aplastic anemia, Anemia, Pediatrics, Internal medicine, Intensive care medicine, Bone marrow